Rozlytrek, approved Aug. 15, targets solid tumors that show rare genetic defects called NTRK gene fusions and ROS1-positive non-small cell lung cancer.
Eli Lilly and Bayer’s drug Vitrakvi is priced at $32,800 per month. It also treats tumors with NTRK gene fusions.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
